Pipeline

CARGO is advancing a pipeline
of next-generation adoptive
CAR T-cell therapies for cancer

Program
CD22 CAR T
Indications
CD19 R/R, LBCL
Phase
90% of Phase 1
Program
Multi-Specific CAR T
Indications
Heme Malignancies
Phase
50% of Lead Selection
Program
Discovery Programs
Indications
Heme & Solid Tumors
Phase
40% of Discovery

*Phase 3 may not be required if the preceding phase is registrational.